The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma.

Citation:
Kilburn LB, Khuong-Quang DA, Hansford JR, ……. Gottardo NG, Gerber NU, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2023; 30(1):207-217

Keywords:
Glioma; braf genomics

Abstract:
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma.